$RCUS
Arcus Biosciences, Inc. Stock $rcus

$rcus Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022001788 Filed on February 23, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$18.01M	$354.5M	$382.9M
YoY Change	90.31%	3636.68%	393.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$23.97M	$23.30M	$72.29M
YoY Change	51.54%	82.14%	70.49%
% of Gross Profit
Research & Development	$61.21M	$49.94M	$256.3M
YoY Change	-7.8%	2.52%	60.87%
% of Gross Profit
Depreciation & Amortization	$1.457M	$1.260M	$3.843M
YoY Change	82.13%	80.0%	23.97%
% of Gross Profit
Operating Expenses	$85.19M	$73.23M	$328.6M
YoY Change	3.62%	19.08%	62.89%
Operating Profit	-$67.18M		$54.25M
YoY Change	-7.65%		-143.67%
Interest Expense	$582.0K	$176.0K	$657.0K
YoY Change	288.0%	10.0%	-52.39%
% of Operating Profit			1.21%
Other Income/Expense, Net	$191.0K	-$260.0K	$397.0K
YoY Change	24.03%		-71.17%
Pretax Income	-$66.99M	$281.2M	$54.65M
YoY Change	-7.72%	-642.3%	-144.48%
Income Tax	$1.000M	$1.815M	$1.815M
% Of Pretax Income		0.65%	3.32%
Net Earnings	-$67.99M	$279.4M	$52.83M
YoY Change	-6.34%	-638.77%	-143.0%
Net Earnings / Revenue	-377.63%	78.81%	13.8%
Basic Earnings Per Share			$0.76
Diluted Earnings Per Share	-$955.0K	$3.143M	$0.71
COMMON SHARES
Basic Shares Outstanding	71.06M	70.25M	69.35M
Diluted Shares Outstanding			73.97M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.214B	$499.3M	$499.3M
YoY Change	46.76%	-31.47%	-31.47%
Cash & Equivalents	$548.8M	$147.9M	$147.9M
Short-Term Investments	$664.8M	$351.4M	$351.4M
Other Short-Term Assets	$18.53M	$15.62M	$15.62M
YoY Change	112.95%	184.0%	184.0%
Inventory
Prepaid Expenses
Receivables	$32.17M	$746.8M	$746.8M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.264B	$1.262B	$1.262B
YoY Change	50.16%	71.48%	71.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.48M	$32.46M	$137.4M
YoY Change	23.55%	200.31%	482.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$128.8M	$182.0M	$182.0M
YoY Change	122.13%	2743.59%	2743.59%
Other Assets	$10.89M	$7.730M	$10.74M
YoY Change	32.77%	23.76%	67.73%
Total Long-Term Assets	$279.2M	$330.1M	$330.1M
YoY Change	199.57%	805.09%	804.52%
TOTAL ASSETS
Total Short-Term Assets	$1.264B	$1.262B	$1.262B
Total Long-Term Assets	$279.2M	$330.1M	$330.1M
Total Assets	$1.543B	$1.592B	$1.592B
YoY Change	65.05%	106.13%	106.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.09M	$10.26M	$10.26M
YoY Change	-26.15%	-34.57%	-34.64%
Accrued Expenses	$16.20M	$24.18M	$51.95M
YoY Change	114.92%	153.39%	69.23%
Deferred Revenue	$89.31M	$102.0M
YoY Change	19.77%	36.79%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$161.3M	$166.1M	$166.1M
YoY Change	22.07%	36.5%	36.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$13.87M	$5.260M	$584.4M
YoY Change	-89.97%	868.69%	294.04%
Total Long-Term Liabilities	$13.87M	$5.260M	$584.4M
YoY Change	-89.97%	868.69%	294.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$161.3M	$166.1M	$166.1M
Total Long-Term Liabilities	$13.87M	$5.260M	$584.4M
Total Liabilities	$746.8M	$750.4M	$750.4M
YoY Change	176.3%	177.96%	177.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$343.3M	-$275.4M
YoY Change	-14.33%	-16.1%
Common Stock	$7.000K	$7.000K
YoY Change	0.0%	16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$796.6M	$841.5M	$841.5M
YoY Change
Total Liabilities & Shareholders Equity	$1.543B	$1.592B	$1.592B
YoY Change	65.05%	106.13%	106.12%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$67.99M	$279.4M	$52.83M
YoY Change	-6.34%	-638.77%	-143.0%
Depreciation, Depletion And Amortization	$1.457M	$1.260M	$3.843M
YoY Change	82.13%	80.0%	23.97%
Cash From Operating Activities	$654.0M	-$62.10M	-$256.2M
YoY Change	-1086.19%	24.45%	-330.43%
INVESTING ACTIVITIES
Capital Expenditures	$2.788M	-$8.506M	$26.08M
YoY Change	-23.43%	431.63%	753.62%
Acquisitions
YoY Change
Other Investing Activities	-$265.3M	$27.42M	$22.21M
YoY Change	-498.91%	2009.23%	-105.15%
Cash From Investing Activities	-$268.1M	$18.91M	-$3.868M
YoY Change	-526.67%	-6404.67%	-99.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$220.2M
YoY Change			-49.23%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.93M	11.67M	237.3M
YoY Change	-93.28%	586.53%	-45.9%
NET CHANGE
Cash From Operating Activities	654.0M	-62.10M	-256.2M
Cash From Investing Activities	-268.1M	18.91M	-3.868M
Cash From Financing Activities	14.93M	11.67M	237.3M
Net Change In Cash	400.9M	-31.52M	-22.70M
YoY Change	83.35%	-35.01%	-119.66%
FREE CASH FLOW
Cash From Operating Activities	$654.0M	-$62.10M	-$256.2M
Capital Expenditures	$2.788M	-$8.506M	$26.08M
Free Cash Flow	$651.2M	-$53.60M	-$282.2M
YoY Change	-1030.88%	10.97%	-361.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001724521
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38419
CY2021	dei	Entity Registrant Name EntityRegistrantName	Arcus Biosciences, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3898435
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	3928 Point Eden Way
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Hayward
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94545
CY2021	dei	City Area Code CityAreaCode	510
CY2021	dei	Local Phone Number LocalPhoneNumber	694-6200
CY2021	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.0001 Per Share
CY2021	dei	Trading Symbol TradingSymbol	RCUS
CY2021	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1378544861
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	71061867
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	52000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3566000
CY2020Q4	us-gaap	Assets Assets	772292000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10261000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15682000
CY2021Q4	rcus	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	29587000
CY2020Q4	rcus	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	18307000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24181000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9543000
CY2021Q4	rcus	Deferred Revenue Related Parties Classified Current DeferredRevenueRelatedPartiesClassifiedCurrent	96981000
CY2020Q4	rcus	Deferred Revenue Related Parties Classified Current DeferredRevenueRelatedPartiesClassifiedCurrent	67571000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	166084000
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young, LLP
CY2021	dei	Auditor Location AuditorLocation	Redwood City, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147914000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	173415000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	351394000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	555231000
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	744535000
CY2020Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	943000
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	744595000
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1049000
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	2227000
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	649000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15620000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5471000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1261750000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	735815000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	181990000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	6440000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32455000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10807000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	104968000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12781000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3005000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	203000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7730000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6246000
CY2021Q4	us-gaap	Assets Assets	1591898000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	102003000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	74571000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	121669000
CY2021Q4	rcus	Deferred Revenue Related Parties Noncurrent DeferredRevenueRelatedPartiesNoncurrent	462217000
CY2020Q4	rcus	Deferred Revenue Related Parties Noncurrent DeferredRevenueRelatedPartiesNoncurrent	127511000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	462217000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	132533000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	116887000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15243000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5260000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	543000
CY2021Q4	us-gaap	Liabilities Liabilities	750448000
CY2020Q4	us-gaap	Liabilities Liabilities	269988000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70781736
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70781736
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65114685
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65114685
CY2021Q4	rcus	Common Stock Shares Outstanding Includes Shares Issued But Subject To Vesting CommonStockSharesOutstandingIncludesSharesIssuedButSubjectToVesting	9946
CY2020Q4	rcus	Common Stock Shares Outstanding Includes Shares Issued But Subject To Vesting CommonStockSharesOutstandingIncludesSharesIssuedButSubjectToVesting	1422784
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	6000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1118058000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	830438000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275354000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-328184000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1261000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	44000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	841450000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	502304000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1591898000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	772292000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	382882000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77517000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15000000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	256348000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	159348000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78481000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	72286000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42404000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25228000
CY2021	us-gaap	Operating Expenses OperatingExpenses	328634000
CY2020	us-gaap	Operating Expenses OperatingExpenses	201752000
CY2019	us-gaap	Operating Expenses OperatingExpenses	103709000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	54248000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-124235000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-88709000
CY2021	rcus	Interest And Other Income Expense Nonoperating Net InterestAndOtherIncomeExpenseNonoperatingNet	657000
CY2020	rcus	Interest And Other Income Expense Nonoperating Net InterestAndOtherIncomeExpenseNonoperatingNet	1377000
CY2019	rcus	Interest And Other Income Expense Nonoperating Net InterestAndOtherIncomeExpenseNonoperatingNet	5201000
CY2021	rcus	Effective Interest On Liability For Sale Of Future Royalties EffectiveInterestOnLiabilityForSaleOfFutureRoyalties	260000
CY2020	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	613000
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.93
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-613000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1202000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	397000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1377000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3999000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	54645000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-122858000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-84710000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1815000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	52830000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-122858000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-84710000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1305000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-20000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	171000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	51525000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-122878000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84539000
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.76
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.24
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69345490
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54787118
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43825991
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.71
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-2.24
CY2019	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.93
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73966267
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54787118
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43825991
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	234942000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	188000
CY2019	rcus	Stock Issued During Period Value Vesting Of Early Exercised Stock Options And Restricted Stock StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedStock	1029000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1029000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8981000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	171000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-84710000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	163842000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	21629000
CY2020	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	3762000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	326246000
CY2020	rcus	Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStock	3366000
CY2020	rcus	Stock Issued During Period Value Vesting Of Early Exercised Stock Option StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOption	848000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1587000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21825000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-20000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-122858000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	502304000
CY2021	rcus	Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStock	9089000
CY2021	rcus	Stock Issued During Period Value Vesting Of Early Exercised Stock Option StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOption	686000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3022000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	54528000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1305000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	52830000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	841450000
CY2021	us-gaap	Profit Loss ProfitLoss	52830000
CY2020	us-gaap	Profit Loss ProfitLoss	-122858000
CY2019	us-gaap	Profit Loss ProfitLoss	-84710000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	54528000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	21825000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	8981000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3843000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3149000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3578000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3214000
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1042000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1202000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-4772000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	46000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2638000
CY2021	rcus	Effective Interest On Liability For Sale Of Future Royalties EffectiveInterestOnLiabilityForSaleOfFutureRoyalties	260000
CY2021	rcus	Receivable From Related Party ReceivableFromRelatedParty	-17092000
CY2020	rcus	Receivable From Related Party ReceivableFromRelatedParty	-943000
CY2019	rcus	Receivable From Related Party ReceivableFromRelatedParty	0
CY2021	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	17046000
CY2020	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	917000
CY2019	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	132000
CY2019	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-83000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5944000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	838000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1982000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3322000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	5374000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	588000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4773000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9272000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1726000
CY2021	rcus	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	8355000
CY2020	rcus	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	13735000
CY2019	rcus	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	1756000
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	10138000
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	4593000
CY2020	rcus	Deferred Revenue From Related Party DeferredRevenueFromRelatedParty	195082000
CY2019	rcus	Deferred Revenue From Related Party DeferredRevenueFromRelatedParty	0
CY2021	rcus	Proceeds From Sale Of Short Term And Long Term Investments ProceedsFromSaleOfShortTermAndLongTermInvestments	51001000
CY2020	rcus	Proceeds From Sale Of Short Term And Long Term Investments ProceedsFromSaleOfShortTermAndLongTermInvestments	1003000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26078000
CY2019	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1743000
CY2019	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	57000
CY2021	rcus	Deferred Revenue From Related Party DeferredRevenueFromRelatedParty	-360884000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-367884000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	188082000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2000000
CY2021	rcus	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1288000
CY2020	rcus	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-993000
CY2019	rcus	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-538000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-498000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	498000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-256171000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	111170000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73462000
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	718865000
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	739658000
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	247755000
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	690074000
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	307343000
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	308892000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3055000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1925000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3868000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-434367000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	59212000
CY2021	rcus	Proceeds From Issuance Of Common Stock From Related Party ProceedsFromIssuanceOfCommonStockFromRelatedParty	220235000
CY2020	rcus	Proceeds From Issuance Of Common Stock From Related Party ProceedsFromIssuanceOfCommonStockFromRelatedParty	164207000
CY2019	rcus	Proceeds From Issuance Of Common Stock From Related Party ProceedsFromIssuanceOfCommonStockFromRelatedParty	0
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	220235000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	433776000
CY2021	rcus	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	5000000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	12111000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4953000
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1217000
CY2021	rcus	Repurchase Of Unvested Shares Of Stock RepurchaseOfUnvestedSharesOfStock	6000
CY2020	rcus	Repurchase Of Unvested Shares Of Stock RepurchaseOfUnvestedSharesOfStock	54000
CY2019	rcus	Repurchase Of Unvested Shares Of Stock RepurchaseOfUnvestedSharesOfStock	94000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	237340000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	438675000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1123000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22699000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	115478000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13127000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	173618000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	58140000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	996000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	71267000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	150919000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	173618000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	58140000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1583000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12000
CY2021	rcus	Unpaid Portion Of Other Assets Included In Accrued Research And Development UnpaidPortionOfOtherAssetsIncludedInAccruedResearchAndDevelopment	1425000
CY2021	rcus	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	686000
CY2020	rcus	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	848000
CY2019	rcus	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	1029000
CY2020	rcus	Unpaid Portion Of Financing Costs Included In Accounts Payable UnpaidPortionOfFinancingCostsIncludedInAccountsPayable	61000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 1. Organization</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Description of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Arcus Biosciences, Inc. (the Company) is a clinical-stage biopharmaceutical company focused on creating best-in-class cancer therapies. Using its robust and highly efficient drug discovery capability, the Company has now advanced six investigational products into clinical development, with its most advanced molecule, an anti-TIGIT antibody, now in two Phase 3 registrational studies. The Company’s deep portfolio of novel small molecules and enabling antibodies allows it to create highly differentiated combination therapies, which the Company is developing to treat multiple large tumor types including lung, colorectal, prostate and pancreatic cancers. The Company expects its clinical-stage portfolio to continue to expand and to include molecules targeting both immuno-oncology and cancer cell-intrinsic pathways. The Company’s vision is to create, develop and commercialize highly differentiated combination cancer therapies that have a meaningful impact on patients. The Company currently has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> investigational products in clinical development: domvanalimab (previously referred to as AB154), etrumadenant (previously referred to as AB928), quemliclustat (previously referred to as AB680), and zimberelimab (previously referred to as AB122), AB308 and AB521.</span></p>
CY2021	rcus	Number Of Investigational Product NumberOfInvestigationalProduct	6
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as related disclosure of contingent assets and liabilities. Estimates were used to determine the standalone selling price of performance obligations and the timing of revenue recognition, the value of stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, uncertain tax positions, and valuation allowance for deferred tax assets. Actual results could differ materially from the Company’s estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147914000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	173415000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3005000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	203000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	150919000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	173618000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">C</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ash equivalents, short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. The Company invests in money market funds, treasury bills and notes, government bonds, commercial paper and corporate notes. The Company limits its credit risk associated with cash equivalents, short-term and long-term investments by placing them with banks and institutions it believes are highly credit worthy and in highly rated investments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span>
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2020	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2019	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2021	rcus	Operating Lease Expiration Year OperatingLeaseExpirationYear	2031
CY2020Q4	rcus	Cares Act And Trailer Bill CARESActAndTrailerBill	0
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	147914000
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	173415000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	351394000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	555231000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	181990000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	6440000
CY2021Q4	rcus	Cash Cash Equivalents And Available For Sale Investments CashCashEquivalentsAndAvailableForSaleInvestments	681298000
CY2020Q4	rcus	Cash Cash Equivalents And Available For Sale Investments CashCashEquivalentsAndAvailableForSaleInvestments	735086000
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2021	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0
CY2020	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0
CY2019	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0
CY2021	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0
CY2020	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0
CY2019	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	682559000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1265000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	681298000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	735042000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	57000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	735086000
CY2021	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	50183000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25095000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17728000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14288000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32455000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10807000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16648000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8632000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4938000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	295000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1815000
CY2021Q4	rcus	Other Accrued Liabilities OtherAccruedLiabilities	780000
CY2020Q4	rcus	Other Accrued Liabilities OtherAccruedLiabilities	616000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	24181000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9543000
CY2021	rcus	Operating Lease Expiration Year OperatingLeaseExpirationYear	2031
CY2021	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	the lease amendment and replaced by two options to extend the lease term for the entire 150,753 square feet then under lease in the Hayward premises for a period of eight years each.
CY2021Q2	rcus	Operating Lease Option To Extend Lease Term OperatingLeaseOptionToExtendLeaseTerm	P8Y
CY2021	rcus	Operating Lease Expiration Date OperatingLeaseExpirationDate	2031-12-31
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7100000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2700000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	300000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	200000
CY2021	rcus	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	4890000
CY2020	rcus	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	2105000
CY2021	rcus	Operating Lease Option To Extend Lease Term OperatingLeaseOptionToExtendLeaseTerm	P8Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.051
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	105000000.0
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	113600000
CY2021Q4	rcus	Lessee Operating Lease Tenant Improvement Allowance Receivable LesseeOperatingLeaseTenantImprovementAllowanceReceivable	8400000
CY2021	rcus	Lessee Operating Lease Tenant Improvement Allowance Receivable Expected Period LesseeOperatingLeaseTenantImprovementAllowanceReceivableExpectedPeriod	P1Y
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5100000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	116900000
CY2019	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1600000
CY2021	rcus	Cash Received From Tenant Improvement Allowances CashReceivedFromTenantImprovementAllowances	2967000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	95401000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	8019000
CY2021	rcus	Recognition Of Tenant Improvement Allowance Receivable Included In Other Current Assets RecognitionOfTenantImprovementAllowanceReceivableIncludedInOtherCurrentAssets	10598000
CY2020	rcus	Recognition Of Tenant Improvement Allowance Receivable Included In Other Current Assets RecognitionOfTenantImprovementAllowanceReceivableIncludedInOtherCurrentAssets	979000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	11198000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	14281000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	14759000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	15255000
CY2021Q4	rcus	Tenant Improvement Allowance Expected To Be Received In Less Than One Year Net Of Current Portion Of Lease Liability TenantImprovementAllowanceExpectedToBeReceivedInLessThanOneYearNetOfCurrentPortionOfLeaseLiability	3332000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	116887000
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	3000000.0
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	15769000
CY2021Q4	rcus	Lessee Operating Lease Liability Payments Due Thereafter LesseeOperatingLeaseLiabilityPaymentsDueThereafter	87236000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	158498000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	36562000
CY2021Q4	rcus	Lessee Operating Lease Tenant Improvement Allowance Receivable LesseeOperatingLeaseTenantImprovementAllowanceReceivable	8381000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	113555000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	382882000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77517000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15000000
CY2021	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	202082000
CY2020	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	7000000
CY2019	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	7000000
CY2021Q4	rcus	Option Continuation Payment Due Upon Second Anniversary Of Agreement OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement	100000000
CY2021Q4	rcus	Deferred Revenues At Amendment Closing Date DeferredRevenuesAtAmendmentClosingDate	165086000
CY2021Q4	rcus	Option Payment For Domvanalimab OptionPaymentForDomvanalimab	275000000
CY2021Q4	rcus	Option Payment For Etrumadenant OptionPaymentForEtrumadenant	250000000
CY2021Q4	rcus	Option Payment For Quemliclustat OptionPaymentForQuemliclustat	200000000
CY2021Q4	rcus	Allocation Of Transaction Price AllocationOfTransactionPrice	890086000
CY2021Q4	rcus	Domvanalimab License DomvanalimabLicense	328838000
CY2021Q4	rcus	Etrumadenant License And Cooperative Research And Development Activities EtrumadenantLicenseAndCooperativeResearchAndDevelopmentActivities	218722000
CY2021Q4	rcus	Quemliclustat License And Cooperative Research And Development Activities QuemliclustatLicenseAndCooperativeResearchAndDevelopmentActivities	175618000
CY2021Q4	rcus	Domvanalimab Cooperative Research And Development Activities DomvanalimabCooperativeResearchAndDevelopmentActivities	34528000
CY2021Q4	rcus	Zimberelimab Cooperative Research And Development Services ZimberelimabCooperativeResearchAndDevelopmentServices	11243000
CY2021Q4	rcus	Access Rights Related To Company S Research And Development Pipeline AccessRightsRelatedToCompanySResearchAndDevelopmentPipeline	84076000
CY2021Q4	rcus	Material Rights To Option Continuation Periods MaterialRightsToOptionContinuationPeriods	37061000
CY2021Q4	rcus	Allocation To Performance Obligations AllocationToPerformanceObligations	890086000
CY2021	rcus	Remaining Capitalized Fees At Closing RemainingCapitalizedFeesAtClosing	3800000
CY2021	rcus	Fees Allocated Among Performance Obligations FeesAllocatedAmongPerformanceObligations	8300000
CY2021Q4	rcus	Capital Stock Shares Authorized CapitalStockSharesAuthorized	410000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9892697
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.88
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3758769
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.03
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	680755
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	13.68
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	950799
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	19.08
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12019912
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.46
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	253620000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12019912
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	19.46
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	253620000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5158246
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.55
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M24D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	133742000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.05
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.57
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.33
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	17400000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6800000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	52400000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	16800000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	7800000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.76
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.24
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	37250
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	31986
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	372774
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term Simplified Method ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod	The Company has opted to use the “simplified method” for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years).
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	52830000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-122858000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-84710000
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	70328234
CY2020	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	56354059
CY2019	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	45385489
CY2021	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	982744
CY2020	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1566941
CY2019	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1559498
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69345490
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54787118
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43825991
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73966267
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54787118
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43825991
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4616019
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12072350
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6450813
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.71
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.24
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	53898000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-123318000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-85141000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	747000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	460000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	431000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	54645000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-122858000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-84710000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1252000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	563000
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	1815000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0081
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	-0.0407
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	0.0415
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	0.0000
CY2021	rcus	Effective Income Tax Rate Reconciliation Nondeductible Expense Benefit Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseBenefitResearchAndDevelopment	-0.1191
CY2020	rcus	Effective Income Tax Rate Reconciliation Nondeductible Expense Benefit Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseBenefitResearchAndDevelopment	0.0310
CY2019	rcus	Effective Income Tax Rate Reconciliation Nondeductible Expense Benefit Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseBenefitResearchAndDevelopment	0.0000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0255
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2735
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1965
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0075
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0018
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0128
CY2021	rcus	Effective Income Tax Rate Reconciliation Nondeductible Expenses And Other EffectiveIncomeTaxRateReconciliationNondeductibleExpensesAndOther	0.0079
CY2020	rcus	Effective Income Tax Rate Reconciliation Nondeductible Expenses And Other EffectiveIncomeTaxRateReconciliationNondeductibleExpensesAndOther	-0.0072
CY2019	rcus	Effective Income Tax Rate Reconciliation Nondeductible Expenses And Other EffectiveIncomeTaxRateReconciliationNondeductibleExpensesAndOther	-0.0007
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0332
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	24183000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	54526000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	13288000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	11209000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9857000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3828000
CY2021Q4	rcus	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6140000
CY2020Q4	rcus	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	9068000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	23557000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2407000
CY2021Q4	rcus	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	25389000
CY2020Q4	rcus	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	3831000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3478000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2062000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	105892000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	86931000
CY2021Q4	rcus	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	22800000
CY2020Q4	rcus	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	2704000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	22800000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2704000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83092000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	84227000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1100000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	33800000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19700000
CY2021Q4	rcus	Operating Loss Carry Forwards With No Expiration Date OperatingLossCarryForwardsWithNoExpirationDate	110500000
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3153000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5400000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5400000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3200000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2325000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1246000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5428000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3153000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2165000
CY2021	rcus	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-50000
CY2020	rcus	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-258000
CY2021	rcus	Purchase Commitments Cancellation Period PurchaseCommitmentsCancellationPeriod	P30D
CY2021Q4	rcus	Liabilities For Indemnification Rights And Agreements LiabilitiesForIndemnificationRightsAndAgreements	0
CY2020Q4	rcus	Liabilities For Indemnification Rights And Agreements LiabilitiesForIndemnificationRightsAndAgreements	0
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1

Files In Submission

Name	View Source	Status
0000950170-22-001788-index-headers.html	Edgar Link	pending
0000950170-22-001788-index.html	Edgar Link	pending
0000950170-22-001788.txt	Edgar Link	pending
0000950170-22-001788-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img114857530_0.jpg	Edgar Link	pending
img114857530_1.gif	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rcus-20211231.htm	Edgar Link	pending
rcus-20211231.xsd	Edgar Link	pending
rcus-20211231_cal.xml	Edgar Link	unprocessable
rcus-20211231_def.xml	Edgar Link	unprocessable
rcus-20211231_htm.xml	Edgar Link	completed
rcus-20211231_lab.xml	Edgar Link	unprocessable
rcus-20211231_pre.xml	Edgar Link	unprocessable
rcus-ex10_18.htm	Edgar Link	pending
rcus-ex10_34.htm	Edgar Link	pending
rcus-ex21_1.htm	Edgar Link	pending
rcus-ex23_1.htm	Edgar Link	pending
rcus-ex31_1.htm	Edgar Link	pending
rcus-ex31_2.htm	Edgar Link	pending
rcus-ex32_1.htm	Edgar Link	pending
rcus-ex32_2.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RCUS
Arcus Biosciences, Inc. Stock $rcus

2022 Q1 Form 10-K Financial Statement

#000095017022001788 Filed on February 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RCUS Arcus Biosciences, Inc. Stock $rcus

2022 Q1 Form 10-K Financial Statement

#000095017022001788 Filed on February 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RCUS
Arcus Biosciences, Inc. Stock $rcus